AG

Ashok K. Gupta

BS Bristol-Myers Squibb: 18 patents #272 of 3,969Top 7%
IP Innate Pharma: 4 patents #28 of 85Top 35%
ML Medimmune Limited: 1 patents #469 of 738Top 65%
📍 Gaithersburg, MD: #80 of 1,746 inventorsTop 5%
🗺 Maryland: #1,286 of 35,612 inventorsTop 4%
Overall (All Time): #227,691 of 4,157,543Top 6%
19
Patents All Time

Issued Patents All Time

Showing 1–19 of 19 patents

Patent #TitleCo-InventorsDate
12209126 Treatment of cancer SHAAD ESSA ABDULLAH, Xuyang SONG 2025-01-28
10688180 Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer Robert Graziano, Su Young Kim, Jon M. Wigginton, Pascale Andre 2020-06-23
10604575 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2020-03-31
10584170 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2020-03-10
10577423 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2020-03-03
10494433 Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma Pascale Andre, Mathieu Blery, Cecile Bonnafous, Luisa Salter-Cid, Michael Robbins 2019-12-03
10323093 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2019-06-18
10323092 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2019-06-18
10316090 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2019-06-11
10316091 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2019-06-11
10308714 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2019-06-04
10266595 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2019-04-23
10266596 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2019-04-23
10266594 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2019-04-23
10138299 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2018-11-27
10072082 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2018-09-11
9856320 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton 2018-01-02
9789182 Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer Robert Graziano, Su Young Kim, Jon M. Wigginton, Pascale Andre 2017-10-17
9212224 Antibodies that bind PD-L1 and uses thereof John P. Cogswell, Stacie M. Goldberg, Maria Jure-Kunkel, Xi-Tao Wang, John M. Wigginton 2015-12-15